Xiaobin Yuan - Concepedia

Author

Xiaobin Yuan

Betta Pharmaceuticals (China)ORCID

Also Known As

Dongwen Wang, X Yuan, X. Yuan, Xiaobin Yuan, Yuan Xiaobin, Yuan, Xiaobin

Publications

Citations

H-Index

Concepts

All Affiliations

Betta Pharmaceuticals (China)Chinese Academy of Medical Sciences & Peking Union Medical College Zhejiang Cancer Hospital Huazhong University of Science and Technology Peking University

About

Xiaobin Yuan is an author at Betta Pharmaceuticals (China) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	315
2	Pathology	2	2	198
3	Engineering	1	1	113
4	Natural Sciences	1	1	36
5	Electrical Engineering	1	1	113

Xiaobin Yuan

Publications

859

Citations

H-Index

Page 1

	Year	Citations
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms David P. Steensma, Martin Wermke, Virginia M. Klimek, Leukemia	2021	169
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial Yunpeng Yang, Jianya Zhou, Jianying Zhou, The Lancet Respiratory Medicine Biomarker AnalysisMedicinePharmacologyPathologyBronchial Neoplasm	2019	135
Modeling and characterization of dielectric-charging effects in RF MEMS capacitive switches Xiaobin Yuan, James C. M. Hwang, David Forehand, IEEE MTT-S International Microwave Symposium Digest, 2005. Electrical EngineeringDielectricsEngineeringSteady-state Charge DensitiesActuation Voltage	2005	113
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) David P. Steensma, Martin Wermke, Virginia M. Klimek, Blood	2019	88
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study Shun Lü, Jianying Zhou, Hong Jian, The Lancet Respiratory Medicine First-line TherapyMedicineRandomised Phase 3Versus IcotinibPathology	2023	63
Intratumoral heterogeneity and genetic characteristics of prostate cancer Bo Wu, Xin Lü, Haibo Shen, International Journal of Cancer UrologyGenitourinary CancerTumor HeterogeneityExome SequencingGenetics	2020	47
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing Yunpeng Yang, Jie Huang, Tao Wang, Journal of Thoracic Oncology	2021	43
Preoperative planning and real-time assisted navigation by three-dimensional individual digital model in partial nephrectomy with three-dimensional laparoscopic system Dongwen Wang, Bin Zhang, Xiaobin Yuan, International Journal of Computer Assisted Radiology and Surgery Geometric ModelingThree-dimensional Laparoscopic SystemLaparoscopyUrologyRobotics	2015	36
Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity Chris Liang, Xiaobin Yuan, Zhilin Shen, Molecular Therapy — Oncolytics	2022	27
Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005). François Guilhot, Jane F. Apperley, Dong-Wook Kim, Blood	2007	25

Page 1